Dissecting the indirect effects caused by vaccines into the basic elements

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 9, 2015, Pages 2142-2157

  Lefebvre, Carla D Scarbrough ^a   Terlinden, Augustin ^b   Standaert, Baudouin ^c  

^a Navigha ^*  (United States)

^b Navigha   (Belgium)

^c GSK   (Belgium)

Author keywords

Age shift; Clustering; Externalities; Force of infection; Herd protection; Rebound effects; Serotype replacement; Vaccination

Indexed keywords

AGE; AGE SHIFTING; DISEASE PREDISPOSITION; DISEASE RE-EMERGENCE; DISEASE TRANSMISSION; DRUG EFFICACY; ENDEMIC DISEASE; EPIDEMIC; HERD IMMUNITY; HUMAN; IMMUNE RESPONSE; INCIDENCE; INFECTION; INNATE IMMUNITY; MATHEMATICAL MODEL; OUTCOME ASSESSMENT; PARAMETERS; PATHOGEN TRANSMISSION; QUALITY ADJUSTED LIFE YEAR; REBOUND; REVIEW; SEROTYPE; TIME; VACCINATION; ADVERSE DRUG REACTION; IMMUNOLOGY;

VACCINE;

DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; IMMUNITY, HERD; VACCINES;

EID: 84954546010     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1052196     Document Type: Review

References (145)

1. Kim TH, Johnstone J, Loeb M. Vaccine herd effect. Scand J Infect Dis 2011; 43: 683-9; PMID:21604922
2. Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decis Making 2003; 23: 76-82; PMID:12583457; http://dx.doi.org/10.1177/0272989X02239651
3. Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics 2008; 26: 191-215; PMID:18282015; http://dx.doi.org/10.2165/00019053-200826030-00004
4. Jit M, Newall AT, Beutels P. Key issues for estimating the impact and cost-effectiveness of seasonal influenza vaccination strategies. Hum Vaccin Immunother 2013; 9: 834-40; PMID:23357859; http://dx.doi.org/10.4161/hv.23637
5. Boulier BL, Tejwant SD, Goldfarb RS. Vaccination Externalities. The B.E. Journal of Economic Analysis and Policy 2007; 7; http://dx.doi.org/10.2202/1935-1682.1487
6. Plans-Rubio P. Evaluation of the establishment of herd immunity in the population by means of serological surveys and vaccination coverage. Hum Vaccin Immunother 2012; 8: 184-8; PMID:22426372; http://dx.doi.org/10.4161/hv.18444
7. Clemens J, Shin S, Ali M. New approaches to the assessment of vaccine herd protection in clinical trials. Lancet Infect Dis 2011; 11: 482-7; PMID:21616458; http://dx.doi.org/10.1016/S1473-3099(10)70318-2
8. Smith PG. Concepts of herd protection and immunity. Ninth Global Vaccine Research Forum and Parallel Satellite Symposia; 2009 December 6–9 Bamako, Mali; Keppel Street, London WCIE 7HT, United Kingdom. Procedia Vaccinol 2; 2010. 134-9; http://dx.doi.org/10.1016/j.provac.2010.07.005
9. Jit M, Brisson M. Modelling the epidemiology of infectious diseases for decision analysis: a primer. Pharmacoeconomics 2011; 29: 371-86; PMID:21504239; http://dx.doi.org/10.2165/11539960-000000000-00000
10. Beutels P, Van Doorslaer E, Van Damme P, Hall J. Methodological issues and new developments in the economic evaluation of vaccines. Expert Rev Vaccines 2003; 2: 649-60; PMID:14711326; http://dx.doi.org/10.1586/14760584.2.5.649
11. Donaghy M, Cameron JC, Friederichs V. Increasing incidence of mumps in Scotland: options for reducing transmission. J Clin Virol 2006; 35: 121-9; PMID:16289903; http://dx.doi.org/10.1016/j. jcv.2005.09.009
12. Edmunds WJ, Medley GF, Nokes DJ. Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. Stat Med 1999; 18: 3263-82; PMID:10602150; http://dx.doi.org/10.1002/(SICI) 1097-0258(19991215)18:23%3c3263::AIDSIM315% 3e3.0.CO;2-3
13. Vynnycky E, White R. An Introduction to Infectious Disease Modelling. Great Clarendon Street, Oxford 0_2 6DP: Oxford University Press; 2011. Section 1.3: Transmission; p. 5-7
14. Fine P, Eames K, Heymann DL. “Herd immunity:” a rough guide. Clin Infect Dis 2011; 52: 911-6; PMID:21427399; http://dx.doi.org/10.1093/cid/cir007
15. Pitman R, Fisman D, Zaric GS, Postma M, Kretzschmar M, Edmunds J, Brisson M. Dynamic transmission modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–5. Value Health 2012; 15: 828-34; PMID:22999132; http://dx.doi.org/10.1016/j.jval.2012.06.011
16. Garnett GP. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis 2005; 191 Suppl 1: S97-106; PMID:15627236; http://dx.doi.org/10.1086/425271
17. Centers for Disease Control and Prevention. Recommendations of the Advisory Committee on Immunization Practices (ACIP): Use of vaccines and immune globulins in persons with altered immunocompetence. MMWR 1993; 42(No. RR-5):[inclusive page numbers].
18. Moss W, Lederman H. Immunization of the immunocompromised host. Clin Focus Immune Deficiencies: Issues Information Curr Topics 1998; 1: 1-8
19. Walker D, Beutels P. WHO guide for standardization of economic evaluations of immunization programmes. CH-1211 Geneva 27, Switzerland: World Health Organization, Department of Immunization, Vaccin Biol; 2008. 100 p. Report No.: WHO/IVB/08.14. Initiative for Vaccine Research (IVR)
20. Bauch CT, Anonychuk AM, Van Effelterre T, Pham BZ, Merid MF. Incorporating herd immunity effects into cohort models of vaccine cost-effectiveness. Med Decis Making 2009; 29: 557-69; PMID:19605882; http://dx.doi.org/10.1177/0272989X09334419
21. Van Vlaenderen I, Van Bellinghen LA, Meier G, Nautrup BP. An approximation of herd effect due to vaccinating children against seasonal influenza -a potential solution to the incorporation of indirect effects into static models. BMC Infect Dis 2013; 13: 25; PMID:23339290; http://dx.doi.org/10.1186/1471-2334-13-25
22. Bos JM, Alphen L, Postma MJ. The use of modeling in the economic evaluation of vaccines. Expert Rev Pharmacoecon Outcomes Res 2002; 2: 443-55; PMID:19807468; http://dx.doi.org/10.1586/14737167.2.5.443
23. Trotter CL, Maiden MC. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines 2009; 8: 851-61; PMID:19538112; http://dx.doi.org/10.1586/erv.09.48
24. Van Effelterre T, Soriano-Gabarro M, Debrus S, Claire Newbern E, Gray J. A mathematical model of the indirect effects of rotavirus vaccination. Epidemiol Infect 2009; 138: 884-97; PMID:20028612; http://dx.doi.org/10.1017/S0950268809991245
25. Rashid H, Khandaker G, Booy R. Vaccination and herd immunity: what more do we know? Curr Opin Infect Dis 2012; 25: 243-9; PMID:22561998; http://dx.doi.org/10.1097/QCO.0b013e328352f727
26. Halloran ME, Struchiner CJ, Longini IM, Jr. Study designs for evaluating different efficacy and effectiveness aspects of vaccines. Am J Epidemiol 1997; 146: 789-803; PMID:9384199; http://dx.doi.org/10.1093/oxfordjournals.aje.a009196
27. Samandari T, Bell BP, Armstrong GL. Quantifying the impact of hepatitis A immunization in the United States, 1995–2001. Vaccine 2004; 22: 4342-50; PMID:15474727; http://dx.doi.org/10.1016/j. vaccine.2004.04.014
28. Wenger JD. Epidemiology of Haemophilus influenzae type b disease and impact of Haemophilus influenzae type b conjugate vaccines in the United States and Canada. Pediatr Infect Dis J 1998; 17: S132-6; PMID:9781746; http://dx.doi.org/10.1097/00006454-199809001-00008
29. Trollfors B, Taranger J, Lagergard T, Sundh V, Bryla DA, Schneerson R, Robbins JB. Immunization of children with pertussis toxoid decreases spread of pertussis within the family. Pediatr Infect Dis J 1998; 17: 196-9; PMID:9535245; http://dx.doi.org/10.1097/00006454-199803000-00005
30. Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, Harrison LH, Schaffner W, Reingold A, Bennett NM, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. Jama 2005; 294: 2043-51; PMID:16249418; http://dx.doi.org/10.1001/jama.294.16.2043
31. Raes M, Strens D, Vergison A, Verghote M, Standaert B. Reduction in pediatric rotavirus-related hospitalizations after universal rotavirus vaccination in Belgium. Pediatr Infect Dis J 2011; 30: e120-5; PMID:21436757; http://dx.doi.org/10.1097/INF.0b013e318214b811
32. Berndsen MR, Erlendsdottir H, Gottfredsson M. Evolving epidemiology of invasive Haemophilus infections in the post-vaccination era: results from a long-term population-based study. Clin Microbiol Infect 2011; 18: 918-23; PMID:22070637; http://dx.doi.org/10.1111/j.1469-0691.2011.03700.x
33. Adam HJ, Richardson SE, Jamieson FB, Rawte P, Low DE, Fisman DN. Changing epidemiology of invasive Haemophilus influenzae in Ontario, Canada: evidence for herd effects and strain replacement due to Hib vaccination. Vaccine 2010; 28: 4073-8; PMID:20398617; http://dx.doi.org/10.1016/j. vaccine.2010.03.075
34. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348: 1737-46; PMID:12724479; http://dx.doi.org/10.1056/NEJMoa022823
35. Hsu HE, Shutt KA, Moore MR, Beall BW, Bennett NM, Craig AS, Farley MM, Jorgensen JH, Lexau CA, Petit S, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 2009; 360: 244-56; PMID:19144940; http://dx.doi.org/10.1056/NEJMoa0800836
36. Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. Bmj 2003; 326: 365-6; PMID:12586669; http://dx.doi.org/10.1136/bmj.326.7385.365
37. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011; 11: 760-8; PMID:21621466; http://dx.doi.org/10.1016/S1473-3099(11)70090-1
38. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease– United States, 1998–2003. MMWR Morb Mortal Wkly Rep 2005; 54(36): 893-7; PMID:16163262
39. Paulke-Korinek M, Kundi M, Rendi-Wagner P, de Martin A, Eder G, Schmidle-Loss B, Vecsei A, Kollaritsch H. Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in Austria. Vaccine 2011; 29: 2791-6; PMID:21320539; http://dx.doi.org/10.1016/j.vaccine.2011.01.104
40. Fitzwater SP, Chandran A, Santosham M, Johnson HL. The worldwide impact of the seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2012; 31: 501-8; PMID:22327872; http://dx.doi.org/10.1097/INF.0b013e31824de9f6
41. Dominguez A, Oviedo M, Carmona G, Batalla J, Bruguera M, Salleras L, Plasencia A. Impact and effectiveness of a mass hepatitis A vaccination programme of preadolescents seven years after introduction. Vaccine 2008; 26: 1737-41; PMID:18325642; http://dx.doi.org/10.1016/j.vaccine.2008.01.048
42. Ong G, Hoon HB, Ong A, Chua LT, Kai CS, Tai GK. A 24-year review on the epidemiology and control of measles in Singapore, 1981–2004. Southeast Asian J Trop Med Public Health 2006; 37: 96-101; PMID:16771219
43. Payne DC, Staat MA, Edwards KM, Szilagyi PG, Weinberg GA, Hall CB, Chappell J, Curns AT, Wikswo M, Tate JE, et al. Direct and indirect effects of rotavirus vaccination upon childhood hospitalizations in 3 US Counties, 2006–2009. Clin Infect Dis 2011; 53: 245-53; PMID:21705316; http://dx.doi.org/10.1093/cid/cir307
44. Zlamy M, Kofler S, Orth D, Wurzner R, Heinz-Erian P, Streng A, Prelog M. The impact of Rotavirus mass vaccination on hospitalization rates, nosocomial Rotavirus gastroenteritis and secondary blood stream infections. BMC Infect Dis 2013; 13: 112; PMID:23452879; http://dx.doi.org/10.1186/1471-2334-13-112
45. Gil E, Noursadeghi M, Brown JS. The clinical and ecological impact of childhood pneumococcal vaccination. Br J Hosp Med (Lond) 2013; 74: 212-6; PMID:23571392; http://dx.doi.org/10.12968/hmed.2013.74.4.212
46. Wasley A, Samandari T, Bell BP. Incidence of hepatitis A in the United States in the era of vaccination. Jama 2005; 294: 194-201; PMID:16014593; http://dx.doi.org/10.1001/jama.294.2.194
47. Armstrong GL, Billah K, Rein DB, Hicks KA, Wirth KE, Bell BP. The economics of routine childhood hepatitis A immunization in the United States: the impact of herd immunity. Pediatrics 2007; 119: e22-9; PMID:17200247; http://dx.doi.org/10.1542/peds.2006-1572
48. Lenne X, Diez Domingo J, Gil A, Ridao M, Lluch JA, Dervaux B. Economic evaluation of varicella vaccination in Spain: results from a dynamic model. Vaccine 2006; 24: 6980-9; PMID:16860909; http://dx.doi.org/10.1016/j.vaccine.2006.04.051
49. Streng A, Grote V, Carr D, Hagemann C, Liese JG. Varicella routine vaccination and the effects on varicella epidemiology -results from the Bavarian Varicella Surveillance Project (BaVariPro), 2006–2011. BMC Infect Dis 2013; 13: 303; PMID:23815523; http://dx.doi.org/10.1186/1471-2334-13-303
50. Guris D, Jumaan AO, Mascola L, Watson BM, Zhang JX, Chaves SS, Gargiullo P, Perella D, Civen R, Seward JF. Changing varicella epidemiology in active surveillance sites–United States, 1995–2005. J Infect Dis 2008; 197 Suppl 2: S71-5; PMID:18419413; http://dx.doi.org/10.1086/522156
51. Dagan R, Leventhal A, Anis E, Slater P, Ashur Y, Shouval D. Incidence of hepatitis A in Israel following universal immunization of toddlers. Jama 2005; 294: 202-10; PMID:16014594; http://dx.doi.org/10.1001/jama.294.2.202
52. Broker M. Indirect effects by meningococcal vaccines: herd protection versus herd immunity. Hum Vaccin 2011; 7: 881-2; PMID:21785283; http://dx.doi.org/10.4161/hv.7.8.16273
53. Goncalves G. Herd immunity: recent uses in vaccine assessment. Expert Rev Vaccines 2008; 7: 1493-506; PMID:19053206; http://dx.doi.org/10.1586/14760584.7.10.1493
54. Brisson M, van de Velde N, Franco EL, Drolet M, Boily MC. Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity. J Infect Dis 2011; 204: 372-6; PMID:21742835; http://dx.doi.org/10.1093/infdis/jir285
55. Arinaminpathy N, Lavine JS, Grenfell BT. Self-boosting vaccines and their implications for herd immunity. Proc Natl Acad Sci U S A 2012; 109: 20154-9; PMID:23169630; http://dx.doi.org/10.1073/pnas.1209683109
56. Coudeville L, Van Rie A, Getsios D, Caro JJ, Crepey P, Nguyen VH. Adult vaccination strategies for the control of pertussis in the United States: an economic evaluation including the dynamic population effects. PLoS One 2009; 4: e6284; PMID:19606227; http://dx.doi.org/10.1371/journal.pone.0006284
57. Burns DL, Meade BD, Messionnier NE. Pertussis resurgence: perspectives from the Working Group Meeting on pertussis on the causes, possible paths forward, and gaps in our knowledge. J Infect Dis 2014; 209 Suppl 1: S32-5; PMID:24626870; http://dx.doi.org/10.1093/infdis/jit491
58. Aguas R, Goncalves G, Gomes MG. Pertussis: increasing disease as a consequence of reducing transmission. Lancet Infect Dis 2006; 6: 112-7; PMID:16439331; http://dx.doi.org/10.1016/S1473-3099(06)70384-X
59. Broutin H, Viboud C, Grenfell BT, Miller MA, Rohani P. Impact of vaccination and birth rate on the epidemiology of pertussis: a comparative study in 64 countries. Proc Biol Sci 2010; 277: 3239-45; PMID:20534609; http://dx.doi.org/10.1098/rspb.2010.0994
60. Guris D, Strebel PM, Bardenheier B, Brennan M, Tachdjian R, Finch E, Wharton M, Livengood JR. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990–1996. Clin Infect Dis 1999; 28: 1230-7; PMID:10451158; http://dx.doi.org/10.1086/514776
61. Trotter CL, Edmunds WJ. Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model. Med Decis Making 2006; 26: 38-47; PMID:16495199; http://dx.doi.org/10.1177/0272989X05284109
62. de Vries R, Kretzschmar M, Schellekens JF, Versteegh FG, Westra TA, Roord JJ, Postma MJ. Cost-effectiveness of adolescent pertussis vaccination for the Netherlands: using an individual-based dynamic model. PLoS One 2010; 5: e13392; PMID:20976213; http://dx.doi.org/10.1371/journal.pone.0013392
63. Lopalco PL, Salleras L, Barbuti S, Germinario C, Bruguera M, Buti M, Dominguez A. Hepatitis A and B in children and adolescents–what can we learn from Puglia (Italy) and Catalonia (Spain)? Vaccine 2001; 19: 470-4; http://dx.doi.org/10.1016/S0264-410X (00)00193-6
64. Bielicki JA, Achermann R, Berger C. Timing of measles immunization and effective population vaccine coverage. Pediatrics 2012; 130: e600-6; PMID:22908102; http://dx.doi.org/10.1542/peds.2012-0132
65. Atkinson WL, Orenstein WA, Krugman S. The resurgence of measles in the United States, 1989–1990. Annu Rev Med 1992; 43: 451-63; PMID:1580601; http://dx.doi.org/10.1146/annurev.me.43.020192.002315
66. Postma MJ, Westra TA, Quilici S, Largeron N. Economic evaluation of vaccines: specificities and future challenges illustrated by recent European examples. Expert Rev Vaccines 2013; 12: 555-65; PMID:23659302; http://dx.doi.org/10.1586/erv.13.36
67. Panagiotopoulos T, Antoniadou I, Valassi-Adam E. Increase in congenital rubella occurrence after immunisation in Greece: retrospective survey and systematic review. Bmj 1999; 319: 1462-7; PMID:10582926; http://dx.doi.org/10.1136/bmj.319.7223.1462
68. Bogaards JA, Coupe VM, Xiridou M, Meijer CJ, Wallinga J, Berkhof J. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence. Epidemiology 2011; 22: 505-15; PMID:21540743; http://dx.doi.org/10.1097/EDE.0b013e31821d107b
69. Salathe M, Bonhoeffer S. The effect of opinion clustering on disease outbreaks. J R Soc Interface 2008; 5: 1505-8; PMID:18713723; http://dx.doi.org/10.1098/rsif.2008.0271
70. Dallaire F, De Serres G, Tremblay FW, Markowski F, Tipples G. Long-lasting measles outbreak affecting several unrelated networks of unvaccinated persons. J Infect Dis 2009; 200: 1602-5; PMID:19827945; http://dx.doi.org/10.1086/644783
71. Sugerman DE, Barskey AE, Delea MG, Ortega-Sanchez IR, Bi D, Ralston KJ, Rota PA, Waters-Montijo K, Lebaron CW. Measles outbreak in a highly vaccinated population, San Diego, 2008: role of the intentionally undervaccinated. Pediatrics 2010; 125: 747-55; PMID:20308208; http://dx.doi.org/10.1542/peds.2009-1653
72. Barskey AE, Glasser JW, LeBaron CW. Mumps resurgences in the United States: A historical perspective on unexpected elements. Vaccine 2009; 27: 6186-95; PMID:19815120; http://dx.doi.org/10.1016/j.vaccine.2009.06.109
73. Mauskopf J, Talbird S, Standaert B. Categorization of methods used in cost-effectiveness analyses of vaccination programs based on outcomes from dynamic transmission models. Expert Rev Pharmacoecon Outcomes Res 2012; 12: 357-71; PMID:22812559; http://dx.doi.org/10.1586/erp.12.11
74. Yi J, Anderson EJ. Rotavirus vaccination: short-term indirect herd protection, long-term uncertainty. Expert Rev Vaccines 2013; 12: 585-7; PMID:23750788; http://dx.doi.org/10.1586/erv.13.43
75. Carrion AF, Martin P. Viral hepatitis in the elderly. Am J Gastroenterol 2012; 107: 691-7; PMID:22290404; http://dx.doi.org/10.1038/ajg.2012.7
76. Boonacker CW, Broos PH, Sanders EA, Schilder AG, Rovers MM. Cost effectiveness of pneumococcal conjugate vaccination against acute otitis media in children: a review. Pharmacoeconomics 2011; 29: 199-211; PMID:21250759; http://dx.doi.org/10.2165/11584930-000000000-00000
77. Pichichero ME, Casey JR. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. Jama 2007; 298: 1772-8; PMID:17940232; http://dx.doi.org/10.1001/jama.298.15.1772
78. Pichichero ME, Casey JR. Evolving microbiology and molecular epidemiology of acute otitis media in the pneumococcal conjugate vaccine era. Pediatr Infect Dis J 2007; 26: S12-6; PMID:18049375; http://dx. doi.org/10.1097/INF.0b013e318154b25d
79. Rozenbaum MH, Sanders EA, van Hoek AJ, Jansen AG, van der Ende A, van den Dobbelsteen G, Rodenburg GD, Hak E, Postma MJ. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. Bmj 2010; 340: c2509; PMID:20519267; http://dx.doi.org/10.1136/bmj. c2509
80. Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, Thomas AR, Harrison LH, Bennett NM, Farley MM, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006; 354: 1455-63; PMID:16598044; http://dx.doi.org/10.1056/NEJMoa051642
81. Munoz-Almagro C, Navarro-Torne A, Pallares R. Epidemiologic and clinical implications of secondgeneration pneumococcal conjugate vaccines. Curr Infect Dis Rep 2013; 15: 184-90; PMID:23381547; http://dx.doi.org/10.1007/s11908-013-0326-4
82. Rozenbaum MH, Boersma C, Postma MJ, Hak E. Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination. Expert Rev Vaccines 2011; 10: 187-99; PMID:21332268; http://dx.doi.org/10.1586/erv.10.163
83. Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011; 378: 1962-73; PMID:21492929; http://dx.doi.org/10.1016/S0140-6736(10)62225-8
84. Gounder PP, Bruce MG, Bruden DJ, Singleton RJ, Rudolph K, Hurlburt DA, Hennessy TW, Wenger J. Effect of the 13-Valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization by Streptococcus pneumoniae–Alaska, 2008-2012. J Infect Dis 2013; 209(8):1251-8; PMID:24273178
85. Zuccotti G, Mameli C, Daprai L, Garlaschi ML, Dilillo D, Bedogni G, Faccini M, Gramegna M, Torresani E. Serotype distribution and antimicrobial susceptibilities of nasopharyngeal isolates of Streptococcus pneumoniae from healthy children in the 13-valent pneumococcal conjugate vaccine era. Vaccine 32: 527-34; PMID:24342249; http://dx.doi.org/10.1016/j.vaccine.2013.12.003
86. Isaacman DJ, Strutton DR, Kalpas EA, Horowicz-Mehler N, Stern LS, Casciano R, Ciuryla V. The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine. Clin Ther 2008; 30: 341-57; PMID:18343273; http://dx. doi.org/10.1016/j.clinthera.2008.02.003
87. Poletti P, Melegaro A, Ajelli M, Del Fava E, Guzzetta G, Faustini L, Scalia Tomba G, Lopalco P, Rizzo C, Merler S, et al. Perspectives on the impact of varicella immunization on herpes zoster. A model-based evaluation from three European countries. PLoS One 2013; 8: e60732; PMID:23613740; http://dx.doi.org/10.1371/journal.pone.0060732
88. Fairley CK, Miller E. Varicella-zoster virus epidemiology– a changing scene? J Infect Dis 1996; 174 Suppl 3: S314-9; PMID:8896538; http://dx.doi.org/10.1093/infdis/174.Supplement_3.S314
89. Marin M, Watson TL, Chaves SS, Civen R, Watson BM, Zhang JX, Perella D, Mascola L, Seward JF. Varicella among adults: data from an active surveillance project, 1995–2005. J Infect Dis 2008; 197 Suppl 2: S94-S100; PMID:18419417; http://dx.doi.org/10.1086/522155
90. Berge JJ, Drennan DP, Jacobs RJ, Jakins A, Meyerhoff AS, Stubblefield W, Weinberg M. The cost of hepatitis A infections in American adolescents and adults in 1997. Hepatology 2000; 31: 469-73; PMID:10655272; http://dx.doi.org/10.1002/hep.510310229
91. Hepatitis A vaccine recommendations. Pediatrics 2007; 120: 189-99; PMID:17606579; http://dx.doi.org/10.1542/peds.2007-1088
92. Bonanni P, Boccalini S, Bechini A. Vaccination against hepatitis A in children: A review of the evidence. Ther Clin Risk Manag 2007; 3: 1071-6; PMID:18516263
93. Srinivasa Rao AS, Chen MH, Pham BZ, Tricco AC, Gilca V, Duval B, Krahn MD, Bauch CT. Cohort effects in dynamic models and their impact on vaccination programmes: an example from hepatitis A. BMC Infect Dis 2006; 6: 174; PMID:17147828; http://dx.doi.org/10.1186/1471-2334-6-174
94. Robinson KA, Baughman W, Rothrock G, Barrett NL, Pass M, Lexau C, Damaske B, Stefonek K, Barnes B, Patterson J, et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995–1998: Opportunities for prevention in the conjugate vaccine era. Jama 2001; 285: 1729-35; PMID:11277827; http://dx.doi.org/10.1001/jama.285.13.1729
95. Zhou F, Harpaz R, Jumaan AO, Winston CA, Shefer A. Impact of varicella vaccination on health care utilization. Jama 2005; 294: 797-802; PMID:16106004; http://dx.doi.org/10.1001/jama.294.7.797
96. Siedler A, Dettmann M. Hospitalization with varicella and shingles before and after introduction of childhood varicella vaccination in Germany. Hum Vaccin Immunother 2014; 10: 3594-600; PMID:25483695; http://dx.doi.org/10.4161/hv.34426
97. Tafuri S, Fortunato F, Cappelli MG, Cozza V, Bechini A, Bonanni P, Martinelli D, Prato R. Effectiveness of vaccination against varicella in children under 5 years in Puglia, Italy 2006–2012. Hum Vaccin Immunother 2015; 11: 214-9; PMID:25483538; http://dx.doi.org/10.4161/hv.36153
98. Marin M, Meissner HC, Seward JF. Varicella prevention in the United States: a review of successes and challenges. Pediatrics 2008; 122: e744-51; PMID:18762511; http://dx.doi.org/10.1542/peds.2008-0567
99. Reynolds MA, Chaves SS, Harpaz R, Lopez AS, Seward JF. The impact of the varicella vaccination program on herpes zoster epidemiology in the United States: a review. J Infect Dis 2008; 197 Suppl 2: S224-7; PMID:18419401; http://dx.doi.org/10.1086/522162
100. Schmid DS, Jumaan AO. Impact of varicella vaccine on varicella-zoster virus dynamics. Clin Microbiol Rev 2010; 23: 202-17; PMID:20065330; http://dx. doi.org/10.1128/CMR.00031-09
101. Shah SS, Wood SM, Luan X, Ratner AJ. Decline in varicella-related ambulatory visits and hospitalizations in the United States since routine immunization against varicella. Pediatr Infect Dis J 2010; 29: 199-204; PMID:19949362; http://dx.doi.org/10.1097/INF.0b013e3181bbf2a0
102. Yih WK, Brooks DR, Lett SM, Jumaan AO, Zhang Z, Clements KM, Seward JF. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998–2003. BMC Public Health 2005; 5: 68; PMID:15960856; http://dx.doi.org/10.1186/1471-2458-5-68
103. Brisson M, Edmunds WJ. Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs. Med Decis Making 2006; 26: 434-46; PMID:16997923; http://dx.doi.org/10.1177/0272989X06290485
104. Gil-Prieto R, Walter S, Gonzalez-Escalada A, Garcia-Garcia L, Marin-Garcia P, Gil-de-Miguel A. Different vaccination strategies in Spain and its impact on severe varicella and zoster. Vaccine 2014; 32: 277-83; PMID:24275483; http://dx.doi.org/10.1016/j.vaccine.2013.11.008
105. Russell ML, Schopflocher DP, Svenson L, Virani SN. Secular trends in the epidemiology of shingles in Alberta. Epidemiol Infect 2007; 135: 908-13; PMID:17291380; http://dx.doi.org/10.1017/S0950268807007893
106. Stein M, Cohen R, Bromberg M, Tasher D, Shohat T, Somekh E. Herpes zoster in a partially vaccinated pediatric population in central Israel. Pediatr Infect Dis J 2012; 31: 906-9; PMID:22627868; http://dx. doi.org/10.1097/INF.0b013e31825d33f9
107. Tanuseputro P, Zagorski B, Chan KJ, Kwong JC. Population-based incidence of herpes zoster after introduction of a publicly funded varicella vaccination program. Vaccine 2011; 29: 8580-4; PMID:21939721; http://dx.doi.org/10.1016/j. vaccine.2011.09.024
108. Civen R, Chaves SS, Jumaan A, Wu H, Mascola L, Gargiullo P, Seward JF. The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination. Pediatr Infect Dis J 2009; 28: 954-9; PMID:19536039; http://dx.doi.org/10.1097/INF.0b013e3181a90b16
109. Hales CM, Harpaz R, Joesoef MR, Bialek SR. Examination of links between herpes zoster incidence and childhood varicella vaccination. Ann Intern Med 2013; 159: 739-45; PMID:24297190; http://dx.doi.org/10.7326/0003-4819-159-11-201312030-00006
110. Jumaan AO, Yu O, Jackson LA, Bohlke K, Galil K, Seward JF. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992–2002. J Infect Dis 2005; 191: 2002-7; PMID:15897984; http://dx.doi.org/10.1086/430325
111. Leung J, Harpaz R, Molinari NA, Jumaan A, Zhou F. Herpes zoster incidence among insured persons in the United States, 1993–2006: evaluation of impact of varicella vaccination. Clin Infect Dis 2011; 52: 332-40; PMID:21217180; http://dx.doi.org/10.1093/cid/ciq077
112. Mullooly JP, Riedlinger K, Chun C, Weinmann S, Houston H. Incidence of herpes zoster, 1997–2002. Epidemiol Infect 2005; 133: 245-53; PMID:15816149; http://dx.doi.org/10.1017/S095026880400281X
113. Carville KS, Riddell MA, Kelly HA. A decline in varicella but an uncertain impact on zoster following varicella vaccination in Victoria, Australia. Vaccine 2010; 28: 2532-8; PMID:20117265; http://dx.doi.org/10.1016/j.vaccine.2010.01.036
114. Heywood AE, Wang H, Macartney KK, McIntyre P. Varicella and herpes zoster hospitalizations before and after implementation of one-dose varicella vaccination in Australia: an ecological study. Bull World Health Organ 2014; 92: 593-604; PMID:25177074; http://dx.doi.org/10.2471/BLT.13.132142
115. Jardine A, Conaty SJ, Vally H. Herpes zoster in Australia: evidence of increase in incidence in adults attribu to varicella immunization? Epidemiol Infect 2011; 139: 658-65; PMID:20727248; http://dx.doi.org/10.1017/S0950268810001949
116. Ladhani SN, Slack MP, Andrews NJ, Waight PA, Borrow R, Miller E. Invasive pneumococcal disease after routine pneumococcal conjugate vaccination in children, England and Wales. Emerg Infect Dis 2013; 19: 61-8; PMID:23259937; http://dx.doi.org/10.3201/eid1901.120741
117. Weinmann S, Chun C, Schmid DS, Roberts M, Vandermeer M, Riedlinger K, Bialek SR, Marin M. Incidence and clinical characteristics of herpes zoster among children in the varicella vaccine era, 2005– 2009. J Infect Dis 2013; 208: 1859-68; PMID:23922376; http://dx.doi.org/10.1093/infdis/jit405
118. Chao DY, Chien YZ, Yeh YP, Hsu PS, Lian IB. The incidence of varicella and herpes zoster in Taiwan during a period of increasing varicella vaccine coverage, 2000–2008. Epidemiol Infect 2012; 140: 1131-40; PMID:21906410; http://dx.doi.org/10.1017/S0950268811001786
119. Goldman GS. Incidence of herpes zoster among children and adolescents in a community with moderate varicella vaccination coverage. Vaccine 2003; 21: 4243-9; PMID:14505905; http://dx.doi.org/10.1016/S0264-410X(03)00459-6
120. Goldman GS. Universal varicella vaccination: efficacy trends and effect on herpes zoster. Int J Toxicol 2005; 24: 205-13; PMID:16126614; http://dx.doi.org/10.1080/10915810591000659
121. Kelly HA, Grant KA, Gidding H, Carville KS. Decreased varicella and increased herpes zoster incidence at a sentinel medical deputising service in a setting of increasing varicella vaccine coverage in Victoria, Australia, 1998 to 2012. Euro Surveill 2014; 19
122. Patel MS, Gebremariam A, Davis MM. Herpes zoster-related hospitalizations and expenditures before and after introduction of the varicella vaccine in the United States. Infect Control Hosp Epidemiol 2008; 29: 1157-63; PMID:18999945; http://dx.doi.org/10.1086/591975
123. Wu PY, Wu HD, Chou TC, Sung FC. Varicella vaccination alters the chronological trends of herpes zoster and varicella. PLoS One 2013; 8: e77709; PMID:24204928; http://dx.doi.org/10.1371/journal. pone.0077709
124. Purdy KW, Hay JW, Botteman MF, Ward JI. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clin Infect Dis 2004; 39: 20-8; PMID:15206048; http://dx.doi.org/10.1086/421091
125. Caro JJ, Getsios D, El-Hadi W, Payne K, O’Brien JA. Pertussis immunization of adolescents in the United States: an economic evaluation. Pediatr Infect Dis J 2005; 24: S75-82; PMID:15876932; http://dx.doi.org/10.1097/01.inf.0000160918.72953.51
126. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010; 17: 1055-65; PMID:20463105; http://dx.doi.org/10.1128/CVI.00131-10
127. Cherry JD. Why do pertussis vaccines fail? Pediatrics 2012; 129: 968-70; PMID:22529282; http://dx.doi.org/10.1542/peds.2011-2594
128. John TJ, Samuel R. Herd immunity and herd effect: new insights and definitions. Eur J Epidemiol 2000; 16: 601-6; PMID:11078115; http://dx.doi.org/10.1023/A:1007626510002
129. Moulton LH, Chung S, Croll J, Reid R, Weatherholtz RC, Santosham M. Estimation of the indirect effect of Haemophilus influenzae type b conjugate vaccine in an American Indian population. Int J Epidemiol 2000; 29: 753-6; PMID:10922355; http://dx.doi.org/10.1093/ije/29.4.753
130. Atkins KE, Shim E, Pitzer VE, Galvani AP. Impact of rotavirus vaccination on epidemiological dynamics in England and Wales. Vaccine 2012; 30: 552-64; PMID:22133508; http://dx.doi.org/10.1016/j. vaccine.2011.11.064
131. Tu HA, Rozenbaum MH, de Boer PT, Noort AC, Postma MJ. An update of “Cost-effectiveness of rotavirus vaccination in the Netherlands: the results of a Consensus Rotavirus Vaccine model”. BMC Infect Dis 2013; 13: 54; PMID:23363553; http://dx.doi.org/10.1186/1471-2334-13-54
132. Rozenbaum MH, Mangen MJ, Giaquinto C, Wilschut JC, Hak E, Postma MJ. Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model. BMC Public Health 2011; 11: 462; PMID:21663620; http://dx.doi.org/10.1186/1471-2458-11-462
133. Standaert B, Gomez JA, Raes M, Debrus S, Velazquez FR, Postma MJ. Impact of rotavirus vaccination on hospitalisations in Belgium: comparing model predictions with observed data. PLoS One 2013; 8: e53864; PMID:23349754; http://dx.doi.org/10.1371/journal. pone.0053864
134. Shim E, Galvani AP. Impact of transmission dynamics on the cost-effectiveness of rotavirus vaccination. Vaccine 2009; 27: 4025-30; PMID:19389452; http://dx. doi.org/10.1016/j.vaccine.2009.04.030
135. Aballea S, Millier A, Quilici S, Caroll S, Petrou S, Toumi M. A critical literature review of health economic evaluations of rotavirus vaccination. Hum Vaccin Immunother 2013; 9: 1272-88; PMID:23571226; http://dx.doi.org/10.4161/hv.24253
136. Lopman BA, Curns AT, Yen C, Parashar UD. Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States. J Infect Dis 2011; 204: 980-6; PMID:21878425; http://dx.doi.org/10.1093/infdis/jir492
137. Marty R, Roze S, Bresse X, Largeron N, Smith-Palmer J. Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe. BMC Cancer 2013; 13: 10; PMID:23298365; http://dx.doi.org/10.1186/1471-2407-13-10
138. Sando N, Kofoed K, Zachariae C, Fouchard J. A Reduced National Incidence of Anogenital Warts in Young Danish Men and Women after Introduction of a National Quadrivalent Human Papillomavirus Vaccination Programme for Young Women -An Ecological Study. Acta Derm Venereol 2014; 94(3):288-92.
139. Brisson M, Laprise JF, Drolet M, Van de Velde N, Franco EL, Kliewer EV, Ogilvie G, Deeks SL, Boily MC. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study. Vaccine 2013; 31: 3863-71; PMID:23830974; http://dx.doi.org/10.1016/j.vaccine.2013.06.064
140. Van de Velde N, Brisson M, Boily MC. Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysis. Vaccine 2010; 28: 5473-84; PMID:20573580; http://dx.doi.org/10.1016/j.vaccine.2010.05.056
141. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007; 13: 28-41; PMID:17370513; http://dx.doi.org/10.3201/eid1301.060438
142. Kahn JA, Brown DR, Ding L, Widdice LE, Shew ML, Glynn S, Bernstein DI. Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics 2012; 130: e249-56; PMID:22778297; http://dx.doi.org/10.1542/peds.2011-3587
143. Bauch CT, Rao AS, Pham BZ, Krahn M, Gilca V, Duval B, Chen MH, Tricco AC. A dynamic model for assessing universal Hepatitis A vaccination in Canada. Vaccine 2007; 25: 1719-26; PMID:17229493; http://dx.doi.org/10.1016/j.vaccine.2006.11.020
144. Taranger J, Trollfors B, Bergfors E, Knutsson N, Sundh V, Lagergard T, Lind-Brandberg L, Zackrisson G, White J, Cicirello H, et al. Mass vaccination of children with pertussis toxoid–decreased incidence in both vaccinated and nonvaccinated persons. Clin Infect Dis 2001; 33: 1004-10; PMID:11528572; http://dx.doi.org/10.1086/322639
145. Lee GM, Murphy TV, Lett S, Cortese MM, Kretsinger K, Schauer S, Lieu TA. Cost effectiveness of pertussis vaccination in adults. Am J Prev Med 2007; 32: 186-193; PMID:17296470; http://dx.doi.org/10.1016/j.amepre.2006.10.016